{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:54:51Z","timestamp":1760234091775,"version":"build-2065373602"},"reference-count":8,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>While the scientific community has been focusing on combating novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is responsible for the current COVID-19 pandemic, we also want to draw your attention to this Special Issue of Vaccines entitled \u201cInfluenza Virus and Vaccine Development\u201d [...]<\/jats:p>","DOI":"10.3390\/vaccines9040383","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T15:30:39Z","timestamp":1618414239000},"page":"383","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research Updates for Influenza Virus and Vaccine Development"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0166-5939","authenticated-orcid":false,"given":"Ewan P.","family":"Plant","sequence":"first","affiliation":[{"name":"Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Xie","sequence":"additional","affiliation":[{"name":"Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rockman, S., Laurie, K., and Barr, I. (2020). Pandemic Influenza Vaccines: What did We Learn from the 2009 Pandemic and are We Better Prepared Now?. Vaccines, 8.","DOI":"10.3390\/vaccines8020211"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Chen, P.L., Tzeng, T.T., Hu, A.Y., Wang, L.H., and Lee, M.S. (2020). Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness. Vaccines, 8.","DOI":"10.3390\/vaccines8040626"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Bazhan, S., Antonets, D., Starostina, E., Ilyicheva, T., Kaplina, O., Marchenko, V., Durymanov, A., Oreshkova, S., and Karpenko, L. (2020). Immunogenicity and Protective Efficacy of Influenza A DNA Vaccines Encoding Artificial Antigens Based on Conservative Hemagglutinin Stem Region and M2 Protein in Mice. Vaccines, 8.","DOI":"10.3390\/vaccines8030448"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Tannig, P., Peter, A.S., Lapuente, D., Klessing, S., Schmidt, A., Damm, D., Tenbusch, M., \u00dcberla, K., and Temchura, V. (2020). Genetic Co-Administration of Soluble PD-1 Ectodomains Modifies Immune Responses against Influenza A Virus Induced by DNA Vaccination. Vaccines, 8.","DOI":"10.3390\/vaccines8040570"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ito, T., Kumagai, T., Yamaji, Y., Sawada, A., and Nakayama, T. (2020). Recombinant Measles AIK-C Vaccine Strain Expressing Influenza HA Protein. Vaccines, 8.","DOI":"10.3390\/vaccines8020149"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kiseleva, I., Isakova-Sivak, I., Stukova, M., Erofeeva, M., Donina, S., Larionova, N., Krutikova, E., Bazhenova, E., Stepanova, E., and Vasilyev, K. (2020). A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults. Vaccines, 8.","DOI":"10.3390\/vaccines8020296"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Carnell, G.W., Trombetta, C.M., Ferrara, F., Montomoli, E., and Temperton, N.J. (2021). Correlation of Influenza B Haemagglutination Inhibiton, Single-Radial Haemolysis and Pseudotype-Based Microneutralisation Assays for Immunogenicity Testing of Seasonal Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9020100"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ambati, A., Luo, G., Pradhan, E., Louis, J., Lin, L., Leib, R.D., Ollila, H.M., Poiret, T., Adams, C., and Mignot, E. (2020). Mass Spectrometric Characterization of Narcolepsy-Associated Pandemic 2009 Influenza Vaccines. Vaccines, 8.","DOI":"10.1101\/2020.08.21.256180"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/4\/383\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:47:49Z","timestamp":1760161669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/4\/383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":8,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["vaccines9040383"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9040383","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2021,4,14]]}}}